SNX 5422

Drug Profile

SNX 5422

Alternative Names: 113; PF-04929113; PF-113; PF-4929113; SNX-5422

Latest Information Update: 07 Dec 2016

Price : $50

At a glance

  • Originator Serenex
  • Developer Esanex; Serenex
  • Class Amides; Antineoplastics; Indazoles; Small molecules
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cancer
  • Phase I Haematological malignancies; Neuroendocrine tumours; Solid tumours
  • Phase Unknown Chronic lymphocytic leukaemia
  • No development reported Lung cancer; Non-Hodgkin's lymphoma

Most Recent Events

  • 22 Nov 2016 Esanex plans a phase I trial for Chronic lymphocytic leukaemia (Combination therapy, Second-line therapy or greater) in USA (PO, Capsule) (NCT02973399)
  • 07 Oct 2016 Safety and efficacy data from a phase I trial in Neuroendocrine tumours presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 01 Oct 2016 Esanex terminates a phase II trial in Cancer (Second-line therapy or greater) in USA (NCT02612285)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top